Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 0.45 |
| ▸ | HTR2A | P28223 | 14/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618725 | 0.90 | ALDH1A1 (0.43) | HTR2CHTR2APRMT5WDR77 | |
| SCHEMBL16238766 | 0.90 | TRPV1 (0.40) | HTR2CHTR2ATRPV1 | |
| SCHEMBL17618745 | 0.90 | HTR2A (0.45) | HTR2CHTR2ATRPV1 | |
| SCHEMBL20631680 | 0.90 | GAA (0.38) | HTR2CHTR2APRMT5WDR77 | |
| SCHEMBL16776268 | 0.88 | PRMT5 (0.35) | HTR2CHTR2APRMT5WDR77 | |
| SCHEMBL19699039 | 0.86 | HTR2C (0.46) | HTR2CHTR2A | |
| SCHEMBL16776273 | 0.86 | FAAH (0.36) | PRMT5WDR77 | |
| SCHEMBL16776272 | 0.85 | PRMT5 (0.42) | PRMT5WDR77TRPV1 | |
| SCHEMBL17618729 | 0.84 | HTR2A (0.44) | HTR2CHTR2A | |
| SCHEMBL16238463 | 0.84 | TSHR (0.47) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HTR2C 4651/4885HTR2A 4386/4885PRMT5 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.